Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

International Myeloma Foundation: CAR-T Cell Therapy

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

Efficacy-safety trade-off and patient selection: A meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies

CAR T-Cell Therapy Resource Center

Interview with Laura R. Dickinson, PA-C: Building a Community CAR-T Partnership

International Myeloma Foundation: CAR-T Cell Therapy

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

Informational Modules for US Healthcare Providers

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Frontiers in Immunology

In vivo CAR T-cell generation: Delivery platforms, clinical progress, and translational barriers

Blood Cancer Discovery

A phase I/II trial of anti-CD22/CD19 CAR-T cell therapy, CART2219.1, in adult and pediatric relapsed/refractory B-ALL

Blood

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

Current Opinion in Oncology

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma

International Journal of Hematology

Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy

Frontiers in Immunology

Efficacy-safety trade-off and patient selection: A meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL

Science Immunology

Genomic correlates of clinical CAR T cell activity

Technology in Cancer Research and Treatment

Leveraging immunotherapy in acute myeloid leukemia treatment: Opportunities and challenges

International Immunopharmacology

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies

European Journal of Nuclear Medicine and Molecular Imaging

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: A DESCAR-T study

ICANS or TIAN? Neurologic Toxicity Following CAR T-Cell Therapy in a Patient With Primary Central Nervous System Lymphoma

Identifying CRS in Patients Who Underwent CAR T-Cell Infusion

Cytopenias After CAR T-cell Therapy: Varying Predictive Markers, Duration

Fast Facts #12: BCMA Targets